Amgen Inc.

AMGN · NASDAQ

Amgen reported FY2025 revenue of $36.75 billion and Q1 2026 revenue of $8.62 billion, with the official record tying the thesis to biologics scale, acquired-product integration, patent cliffs, pipeline execution, leverage and cash conversion.

Follow Add to Watchlist Ask Question

NASDAQ AMGN Coverage Bootstrap Amgen Inc.

Latest ReportMay 19, 2026Amgen: the post-Horizon biotech has to turn scale into deleveraging and pipeline proofView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.